
According to Benzinga Pro, during Q4, Atea Pharmaceuticals (NASDAQ:AVIR) earned $117.13 million, a 515.45% increase from the preceding quarter. Atea Pharmaceuticals also posted a total of $192.18 million in sales, a 485.72% increase since Q3. Atea Pharmaceuticals collected $32.81 million in revenue during Q3, but reported earnings showed a $28.19 million loss.